CN102911265B - Recombination variant of human nerve growth factors and preparation method thereof - Google Patents
Recombination variant of human nerve growth factors and preparation method thereof Download PDFInfo
- Publication number
- CN102911265B CN102911265B CN201110223536.6A CN201110223536A CN102911265B CN 102911265 B CN102911265 B CN 102911265B CN 201110223536 A CN201110223536 A CN 201110223536A CN 102911265 B CN102911265 B CN 102911265B
- Authority
- CN
- China
- Prior art keywords
- rhngf
- human nerve
- preparation
- restructuring
- growth factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 108010025020 Nerve Growth Factor Proteins 0.000 title abstract description 9
- 102000007072 Nerve Growth Factors Human genes 0.000 title abstract 4
- 230000006798 recombination Effects 0.000 title abstract 3
- 238000005215 recombination Methods 0.000 title abstract 3
- 150000001413 amino acids Chemical class 0.000 claims abstract description 14
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 14
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims abstract description 8
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 4
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 4
- 210000005036 nerve Anatomy 0.000 claims description 11
- 239000002299 complementary DNA Substances 0.000 claims description 9
- 239000003102 growth factor Substances 0.000 claims description 9
- 239000013612 plasmid Substances 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 6
- 102000002933 Thioredoxin Human genes 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 108060008226 thioredoxin Proteins 0.000 claims description 6
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 claims description 5
- 238000003776 cleavage reaction Methods 0.000 claims description 5
- 238000005520 cutting process Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 230000007017 scission Effects 0.000 claims description 5
- 229940094937 thioredoxin Drugs 0.000 claims description 5
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000004587 chromatography analysis Methods 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 238000005267 amalgamation Methods 0.000 claims description 3
- 239000013613 expression plasmid Substances 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 229920002684 Sepharose Polymers 0.000 claims description 2
- 238000013016 damping Methods 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 239000013604 expression vector Substances 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 abstract description 11
- 230000004071 biological effect Effects 0.000 abstract description 3
- 108010033276 Peptide Fragments Proteins 0.000 abstract 1
- 102000007079 Peptide Fragments Human genes 0.000 abstract 1
- 238000001308 synthesis method Methods 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000015336 Nerve Growth Factor Human genes 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 241000287828 Gallus gallus Species 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 108700005078 Synthetic Genes Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000003594 spinal ganglia Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- -1 G glycine Chemical class 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100023152 Scinderin Human genes 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 229940053128 nerve growth factor Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007514 neuronal growth Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 108010073419 scinderin Proteins 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention discloses a recombination variant (rhNGF) of human nerve growth factors and a preparation method thereof. According to the recombination variant of the human nerve growth factors designed by a molecular structure research, ten SSSHPIFHRG amino acids are missed and two GA amino acids are excess at the N end of a peptide fragment, after that a sequence starting from EFSV is same as the normal sequence of the human nerve growth factors. CDNA of rhNGF is obtained with a gene synthesis method, engineering bacteria are built to express, an rhNGF fusion protein is obtained, the rhNGF fusion protein is cut by hydroxylamine and then is purified to obtain the purified rhNGF, and the purified rhNGF has natural biological activity.
Description
Growth factor of human nerve (hNGF) is a kind of biologically active factors that nerve reparation function is had to regulating effect in human body, and to promoting neural growth, the regeneration of injured nerve has decisive role.At present hNGF does not all go public both at home and abroad as medicine, only has China to ratify the NGF clinical application of mouse source, but the threat that mouse source NGF pollutes because of species variation and virus reorganized products substitution at last.With genetically engineered Restruction growth factor of human nerve, it is unique approach.RhNGF has important clinical value, will fill up the blank of international neural repair medicine.China has nerve injury patients up to a million every year, and market outlook are considerable.
We have invented a kind of hNGF restructuring varient of transforming acquisition by protein engineering and preparation method thereof.The growth factor of human nerve end of natural radioactivity is Ser-Ser-Ser-Arg-Pro-Ile-Phe-His-Arg-Gly-Glu-Phe-Ser-Val-Cys-Asn-Ser etc.We are by the further investigation to its molecular structure, the new texture of hNGF restructuring varient has been proposed, this restructuring varient (rhNGF) is characterised in that recombinant expressed hNGF peptide section holds first amino acid to start to have lacked S Serine from N, S Serine, S Serine, H Histidine, P proline(Pro), I Isoleucine, F phenylalanine, H Histidine, R arginine, 10 amino acid such as G glycine, many G glycine, two amino acid of A L-Ala, and from E L-glutamic acid, F phenylalanine, S Serine, V α-amino-isovaleric acid and backward amino acid start to meet hNGF normal sequence, from bulk molecule amount, 8 amino acid have been lacked.The protein engineering transformation that we carry out hNGF by above-mentioned to obtain drug effect better, more stable hNGF recombinant mutant (rhNGF), it is the biomolecules with new texture, is beneficial to new drug development and clinical application.
Example explanation:
1. the acquisition of goal gene
In order to obtain the cDNA of people NGF restructuring varient, we adopt the synthetic method of full gene to obtain the cDNA of rhNGF.
The synthetic method of salvage that adopts of full gene is carried out.Gene order design is according to the gene order of the hNGF of our molecular designing and reference report.The sequence that 5 ' end of the hNGF gene order of our design contains Kpn1 restriction enzyme site and coding azanol cleavage site, 3 ' end contains Xba1 restriction enzyme site and termination codon TGA.Synthetic gene implementation sequence is shown in Fig. 1.
Fig. 1 .rhNGF synthetic gene implementation sequence
2. gene sequencing
By the cDNA of the rhNGF of synthetic, insertion vector pThioHis A, carries out forward order-checking (sequenator: ABI PRISM) with synthetic sequencing primer.
Order-checking collection of illustrative plates is used tricks to calculate machine-readable order, obtain cDNA sequence and translate into corresponding amino acid, cDNA and the consensus amino acid sequence of the hNGF of our design of result.Show that the cDNA that we clone the rhNGF obtaining is correct.
3. the structure of expression plasmid
The cDNA of rhNGF is inserted in pBV220 and directly expressed, and expression product forms insoluble occlusion body, need to obtain activated rhNGF through denature and renature.Because rhNGF is containing three pairs of disulfide linkage, renaturation is very difficult, causes productive rate very low.In order to obtain the solution expression with high efficiency of rhNGF, we carry out amalgamation and expression rhNGF and escherichia coli thioredoxin thioredoxin, and thioredoxin can guide albumen thereafter correctly folding, is solubility expression, tool natural biological is learned active, has avoided a difficult problem for sex change renaturation.
What cutting method was used is oxammonium hydrochloride patterning method.Oxammonium hydrochloride is the Asn-Gly peptide bond in scinderin specifically, and producing N end is the polypeptide of Gly.We find in rhNGF polypeptide containing azanol cleavage site Asn-Gly, still selected azanol cleavage site Asn-Gly be tie point and thioredoxin amalgamation and expression rhNGF.The fusion rotein of expressing is with discharging rhNGF after azanol cutting, and its initial amino acid is Gly, and aminoacid sequence is after this consistent with rhNGF sequence.Gly is similar to Met character, and being placed on N end does not all affect the activity of albumen, moreover the N terminal amino acid of hNGF is inessential to activity, and first 8 amino acid of its N end will be hydrolyzed with practical function in human body.
Azanol is the eubolism product in human body, and oxammonium hydrochloride cost is low, and cleavage specificity is good, and cutting efficiency is high, is applicable to suitability for industrialized production.
We select plasmid pThioHis A as expression vector (Invitrogen company product), and it contains promotor Ptrc promotor, thioredoxin leading peptide and terminator aspA terminator, and Amp resistant gene.We insert synthetic rhNGF cDNA between the Kpn1-Xba1 of above-mentioned plasmid by the fragment after Kpn1-Xba1 double digestion, are built into expression plasmid pTHNGF.
Host Strains is selected e. coli jm109 (purchased from Invitrogen company).The genotype of e. coli jm109 is: recA1supE44 endA1 hsdR17 gyrA96 relA1 thi Δ (lac-proAB) F ' [traD36proAB
+lacI
qlacZ Δ M15].
Plasmid pTHNGF is transformed into e. coli jm109, forms engineering bacteria pTHNGF/JM109.Be stored in 15% glycerine, be frozen in-70 ℃, be original species word bank.
The calibrating of 4.rhNGF engineering bacteria
4.1 ne ar, cultural characteristic, physio-biochemical characteristics
From original species word bank, get the pTHNGF/JM109 engineering bacteria that a glycerine is preserved, be seeded in LBA substratum, 37 ℃ are swayed cultivation 16 hours, with 10% ratio, be inoculated into (LB+0.1mg/ml Amp) in LBA substratum again, continue to cultivate 3 hours, as seed liquor, carry out the following inspection:
4.1.1 ne ar
With after seed liquor coating slide, gramstaining microscopy.Engineering bacteria is Gram-negative, and thalline is direct rod shape, edge clear, and the blunt circle in two ends, size is basically identical, has no other living contaminants.
4.1.2 cultural characteristic
With seed liquor line, LBA is dull and stereotyped, cultivates 20 hours for 37 ℃, and naked eyes are visible: bacterium colony is circular, the smooth of the edge, and bacterium colony is full, and surface wettability, smooth, is creamy white, and matrix has no pigment formation.
4.1.3 physio-biochemical characteristics
Can utilize glucose, lactose, glycerine as carbon source, can not utilize fructose, inositol.Indole reaction is positive.V.P. reaction is negative, not gelatin hydrolysate.
4.2 antibiotics resistance features
Unconverted Host Strains BL21 grows on LB substratum, and (Amp:0.1mg/ml) do not grow on LBA substratum.
Engineering bacteria pTHNGF/JM109 after conversion well-grown all on LB substratum and LBA substratum.
Show that engineering bacteria pTHNGF/JM109 has the resistance of penbritin.
4.3 plasmid enzyme restriction atlas analysis
From above-mentioned seed liquor, extract plasmid pTHNGF, carry out enzyme and cut evaluation.With KpnI-XbaI and KpnI-PstI, all can cut out the small band of 370bp, can cut out the small band of about 340bp with EcoRI-PstI, enzyme is cut qualification result and is all met plasmid design, illustrates that plasmid pTHNGF builds correct.
The expression of 4.4 engineering bacterias and the acquisition of expression product
PTHNGF/JM109 seed liquor is inoculated in LBA substratum with 1% ratio, and 37 ℃ grow to OD
600be about 0.5, add IPTG to 1mM as inductor, induce 5 hours for 37 ℃, results thalline, after washing, sampling cracking, carries out SDS-PAGE electrophoretic analysis.Thalline after visible induction has more a dense protein band at 26kD place than blank, and with the rhNGF fusion protein molecule amount 26kD equal and opposite in direction that will express, through thin layer scanning, this band accounts for the 10-20% left and right of bacterial protein.
The thalline of expressing is carried out to carrying out ultrasonic bacteria breaking, and high speed centrifugation.Precipitation and supernatant are carried out to SDS-PAGE electrophoresis.The rhNGF fusion rotein of visible expression concentrates in supernatant, with soluble form, expresses, and tool natural radioactivity, does not need through denature and renature.
The method discharging through osmotic pressure, is discharged into the solvable rhNGF fusion rotein major part in Bacillus coli cells in damping fluid, after azanol cutting, through Ni chelating chromatography column and CM-Sepharose chromatography column purifying, obtains the rhNGF of purifying.
5. expression product structural identification data
5.1 specificity identification experiments
The rhNGF product of purifying is done immunoblotting and is identified, result and anti-hNGF antibody are positive.Show this product and anti-hNGF antibody generation immune response.
5.2N terminal Amino Acid Sequence Analysis
The rhNGF of purifying is carried out to N terminal Amino Acid Sequencing, and sequencing result shows that 15 aminoacid sequences of N end are:
Gly-Ala-Glu-Phe-Ser-Val-Cys-Asp-Ser-Val-Ser-Val-Trp-Val-Gly
Be that N terminal amino acid sequence and design meet.
6. determination of activity
Adopt chick embryonic dorsal root ganglion method to measure, be specially and take DMEM as mother liquor, in the substratum containing 20% chicken plasma and 15% chick embryo extract, utilize esa brown chicken embryo lumbar vertebrae dorsal root ganglion, under the stimulation of the NGF that is 30ng/ml at final concentration, cultivate 36h.After testing, its biologic activity of the rhNGF of purifying and mouse source Nerve Growth Factor Activity, at an order of magnitude, reach 10
5more than u/mg.
By above step, we have carried out protein engineering transformation to hNGF, to obtaining the hNGF recombinant mutant (rhNGF) that drug effect is better, biological activity is more stable, are beneficial to study on mechanism and the clinical application of growth factor of human nerve.
Claims (4)
1. a growth factor of human nerve restructuring varient (rhNGF), is characterized in that being comprised of aminoacid sequence GAEFSV CDSVSVWVG DKTTATDIK GKEVMVLGE VNINNSVFK EYFFETKCR DPNPVDSGC RGIDSKHWN SYCTTTHTF VKALTMDGK EAAWRFIRI DTACVCVLS RKAVR.
2. the preparation method of growth factor of human nerve restructuring varient according to claim 1, it is characterized in that, select plasmid pThioHis A as expression vector, it contains promotor Ptrc promotor, thioredoxin leading peptide and terminator aspA terminator, and Amp resistant gene; Synthetic rhNGF cDNA is inserted between the Kpnl-Xbal of above-mentioned plasmid by the fragment after Kpnl-Xbal double digestion, be built into expression plasmid pTHNGF.
3. the preparation method of growth factor of human nerve restructuring varient according to claim 1, it is characterized in that, selected Asn-Gly is tie point and thioredoxin amalgamation and expression rhNGF, with the oxammonium hydrochloride Asn-Gly peptide bond in cleavage of fusion proteins specifically, producing N end is the rhNGF polypeptide of Gly again.
4. the preparation method of growth factor of human nerve restructuring varient according to claim 1, it is characterized in that, purifying is by osmotic pressure method, the solvable rhNGF fusion rotein major part in Bacillus coli cells to be discharged in damping fluid, after azanol cutting, with Ni chelating chromatography column and CM-Sepharose chromatography column, purify and obtain.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110223536.6A CN102911265B (en) | 2011-08-05 | 2011-08-05 | Recombination variant of human nerve growth factors and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110223536.6A CN102911265B (en) | 2011-08-05 | 2011-08-05 | Recombination variant of human nerve growth factors and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102911265A CN102911265A (en) | 2013-02-06 |
CN102911265B true CN102911265B (en) | 2014-02-05 |
Family
ID=47609863
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110223536.6A Expired - Fee Related CN102911265B (en) | 2011-08-05 | 2011-08-05 | Recombination variant of human nerve growth factors and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102911265B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103880943A (en) * | 2014-01-20 | 2014-06-25 | 厦门北大之路生物工程有限公司 | Method for preparing rhNGF mature peptide |
CN107973848B (en) * | 2017-12-28 | 2020-10-16 | 未名生物医药有限公司 | Method for separating natural sequence nerve growth factor from mixture |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101932591A (en) * | 2007-07-09 | 2010-12-29 | 健泰科生物技术公司 | Prevention of disulfide bond reduction during recombinant production of polypeptides |
-
2011
- 2011-08-05 CN CN201110223536.6A patent/CN102911265B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101932591A (en) * | 2007-07-09 | 2010-12-29 | 健泰科生物技术公司 | Prevention of disulfide bond reduction during recombinant production of polypeptides |
Non-Patent Citations (2)
Title |
---|
王妍.重组人神经生长因子在大肠杆菌中的可溶表达.《第七次全国生物制品学术会议论文汇编》.2003,第151页左栏第一段,最后一段和右栏第二段. |
重组人神经生长因子在大肠杆菌中的可溶表达;王妍;《第七次全国生物制品学术会议论文汇编》;20031231;第151页左栏第一段,最后一段和右栏第二段 * |
Also Published As
Publication number | Publication date |
---|---|
CN102911265A (en) | 2013-02-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017206326A1 (en) | Recombinant human collagen, and coding gene and manufacturing method thereof | |
CN110845603A (en) | Human collagen 17-type polypeptide, production method and use thereof | |
CN114805551B (en) | Recombinant type III collagen and preparation method thereof | |
RU2015125491A (en) | DIRECTED THERAPEUTIC CHIMERIC PROTEINS OF LYSOSOMAL ENZYMES AND THEIR APPLICATION | |
JPH07502163A (en) | Synthetic storage protein with defined structure containing programmable levels of essential amino acids for improved nutritional value of plants | |
CN101519446A (en) | Method for preparing recombinant human insulin and analogs of recombinant human insulin | |
CN101240033B (en) | Fusion protein of insulin secretion accelerating peptide and human serum albumin, and preparation method thereof | |
CN110724187B (en) | Recombinant engineering bacterium for efficiently expressing liraglutide precursor and application thereof | |
CN104592381A (en) | Preparation method of liraglutide intermediate polypeptide | |
CN108265065B (en) | Recombinant artemisia annua 1-class allergen protein and application thereof | |
CN105198972A (en) | Method for preparing high purity recombinant human brain natriuretic peptides | |
CN114181321B (en) | Lateolabrax japonicus FGF6A, FGF6B and FGF18 recombinant protein and preparation method and application thereof | |
CN102911265B (en) | Recombination variant of human nerve growth factors and preparation method thereof | |
CN112239760B (en) | Recombinant engineering bacterium for efficiently expressing recombinant hGH (human growth hormone) and construction method and application thereof | |
CN107056925A (en) | People FGF21 mutant, preparation method and the usage | |
CN112480227B (en) | Protein for improving pathogenic bacterium resistance of sturgeon and preparation method and application thereof | |
CN104250304B (en) | The vaccine combination of a kind of fusion protein and its coding and application | |
CN108265064B (en) | Recombinant artemisia annua 3-class allergen protein and application thereof | |
CN109289046A (en) | A kind of Fusobacterium nucleatum FomA protein vaccine and preparation method and application | |
CN101897953B (en) | Non-invasive high-penetrability epidermal growth factor and application thereof | |
CN101875699A (en) | Fusion protein of human epidermal growth factor and metallothionein and preparation method and application thereof | |
CN102533683B (en) | Phyllostachys edulis violaxanthin deepoxidase (PeVDE) protein, coding gene thereof and applications thereof | |
CN101955969A (en) | Construction and application for general efficient and soluble pronucleus fusion expression vector | |
CN104725485B (en) | One kind restructuring active peptide and its synchronic preparation method | |
CN108117599A (en) | The recombination expression and purification process of Ssm6a and its fusion protein used |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140205 |